Perlmutter named CEO of Eikon, a biotech with $148M to apply Nobel-winning tech to undruggable targets Portfolio News / By Karina Tin May 5, 2021 Perlmutter named CEO of Eikon, a biotech with $148M to apply Nobel-winning tech to undruggable targets Read More »
Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 Diabetes Portfolio News / By Karina Tin May 04, 2021 Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 Diabetes Read More »
Escient Pharmaceuticals Names Svetlana Makhni As Chief Financial Officer Portfolio News / By Karina Tin May 3, 2021 Escient Pharmaceuticals Names Svetlana Makhni As Chief Financial Officer Read More »
Synthekine Appoints Internationally Recognized Cancer Immunotherapy Leader Naiyer Rizvi, M.D., as Chief Medical Officer Portfolio News / By Karina Tin May 3, 2021 Synthekine Appoints Internationally Recognized Cancer Immunotherapy Leader Naiyer Rizvi, M.D., as Chief Medical Officer Read More »
NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors Portfolio News / By Karina Tin April 28, 2021 NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors Read More »
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors Portfolio News / By Karina Tin April 21, 2021 Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors Read More »
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy Portfolio News / By Karina Tin April 19, 2021 Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy Read More »
Surrozen and Consonance-HFW Acquisition Corp. Announce Business Combination, Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration Portfolio News / By Karina Tin April 15, 2021 Surrozen and Consonance-HFW Acquisition Corp. Announce Business Combination, Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration Read More »
Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin April 13, 2021 Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update Read More »
Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities Portfolio News / By Karina Tin April 10, 2021 Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities Read More »
